Upstream therapy for atrial fibrillation

Circulation Journal

Volumn 71, Issue SUPPL. A, 2007, Pages

  Kumagai, Koichiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Angiotensin; Arrhythmia; Atrial fibrillation; Inflammation; Statins

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; ATORVASTATIN; CALCIUM; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; MITOGEN ACTIVATED PROTEIN KINASE; PRAVASTATIN; VERAPAMIL;

COMBINATION CHEMOTHERAPY; FIBROSING ALVEOLITIS; HEART ATRIUM; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; INFLAMMATION; MONOTHERAPY; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; HEART CONDUCTION SYSTEM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; TREATMENT OUTCOME;

EID: 34347208265     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.A75     Document Type: Review

References (57)

1. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96: 3157-3163.
2. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999; 100: 87-95.
3. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
4. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-2681.
5. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
6. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
7. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204.
8. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
9. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: Time course and mechanisms. Circulation 1996; 94: 2968-2974.
10. Tieleman RG, De Langen C, Van Gelder IC, de Kam PJ, Grandjean J, Bel KJ, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95: 1945-1953.
11. Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessie MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: Roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997; 96: 3710-3720.
12. Everett THt, Li H, Mangrum JM, McRury ID, Mitchell MA, Redick JA, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 2000; 102: 1454-1460.
13. Tieleman RG, Van Gelder IC, Crijns HJ, De Kam PJ, Van Den Berg MP, Haaksma J, et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31: 167-173.
14. Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96: 1542-1550.
15. Shenasa M, Kus T, Fromer M, LeBlanc RA, Dubuc M, Nadeau R. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol 1988; 62: 403-407.
16. Lee SH, Yu WC, Cheng JJ, Hung CR, Ding YA, Chang MS, et al. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000; 101: 200-206.
17. Fareh S, Benardeau A, Thibault B, Nattel S. The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999; 100: 2191-2197.
18. Ramanna H, Elvan A, Wittkampf FH, de Bakker JM, Hauer RN, Robles de Medina EO. Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. J Am Coll Cardiol 2001; 37: 1403-1407.
19. Kumagai K, Matsuo K, Ono M, Yamanouchi Y, Moroe K, Hamasaki N, et al. Effects of verapamil on electrophysiological properties in paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 1993; 16: 309-316.
20. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: Insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003; 107: 1440-1446.
21. Shinagawa K, Mitamura H, Ogawa S, Nattel S. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res 2002; 54: 438-446.
22. Willems R, Sipido KR, Holemans P, Ector H, Van de Werf F, Heidbuchel H. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. J Cardiovasc Electrophysiol 2001; 12: 1387-1392.
23. Sideris DA, Toumanidis ST, Tselepatiotis E, Kostopoulos K, Stringli T, Kitsiou T, et al. Atrial pressure and experimental atrial fibrillation. Pacing Clin Electrophysiol 1995; 18: 1679-1685.
24. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 833-842.
25. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997; 96: 1686-1695.
26. Kijima K, Matsubara H, Murasawa S, Maruyama K, Mori Y, Ohkubo N, et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res 1996; 79: 887-897.
27. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-1609.
28. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
29. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
30. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96: 3542-3548.
31. Page PL, Plumb VJ, Okumura K, Waldo AL. A new animal model of atrial flutter. J Am Coll Cardiol 1986; 8: 872-879.
32. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-521.
33. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111.
34. Basso C, Corrado D, Rossi L, Thiene G. Ventricular preexcitation in children and young adults: Atrial myocarditis as a possible trigger of sudden death. Circulation 2001; 103: 269-275.
35. Fromer M, Genton C, Schlaepfer J, Goy JJ, Kappenberger L. Is there an isolated arrhythmogenic right atrial myocarditis? Eur Heart J 1990; 11: 566-571.
36. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235.
37. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
38. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-119.
39. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
40. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
41. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844.
42. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
43. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281-287.
44. Jones SP, Teshima Y, Akao M, Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 2003; 93: 697-699.
45. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002; 53: 911-920.
46. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110: 2313-2319.
47. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345.
48. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
49. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931.
50. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44: 159-164.
51. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
52. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557.
53. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004; 1: 669-675.
54. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995; 1: 355-363.
55. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336.
56. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.
57. Zaman AG, Kearney MT, Schecter C, Worthley SG, Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004; 147: 823-827.